@article{Laniush_Urbanovych_2020, title={EATING DISORDERS IN PATIENTS WITH TYPE 2 DIABETES}, volume={73}, url={https://www.jpep.endocrinology.org.ua/index.php/1/article/view/90}, DOI={10.21856/j-PEP.2020.3.15}, abstractNote={<p>This review analyzes the impact of eating disorders on type 2 diabetes mellitus. The most common types of eating disorders among people suffering from diabetes are binge eating and night-eating syndrome. They are accompanied by excessive intake of food and worsen the course of type 2 diabetes: make it difficult to reach the target levels of glycemia and lipidogram, normalization of body weight. Lifestyle change, namely diet and exercise, is one of the main treatments for diabetes. However, in the presence of the eating disorders adherence to dietary recommendations becomes a difficult task for this category of patients. In addition, there is a large percentage of patients with binge eating and night-eating syndrome who are not aware of their problem and are not trying to change their own lifestyle, which hinders treatment of the main disease - type 2 diabetes. The main regulators of eating behavior in humans are leptin and ghrelin. By binding to the receptors of the center of hunger and satiety located in the hypothalamus, these hormone-like substances affect the frequency of food intake and control the body’s energy balance. Leptin has orexogenic properties; it forms a sense of satiety in the body. However, in patients with obesity and diabetes its level is increased due to the development of leptin resistance. In turn, ghrelin has the opposite properties: it creates a feeling of hunger. Its concentration in obese and diabetic people remains low compared to healthy individuals. According to scientific literature, the levels of leptin and ghrelin in patients with obesity, type 2 diabetes and eating disorders are different from healthy individuals. However, their role in the formation of eating habits and disorders is still poorly understood. Further studies are needed to determine the effectiveness of determining leptin and ghrelin levels in patients with type 2 diabetes to predict the development of eating disorders. It is assumed that the timely treatment of eating disorders will quickly achieve sustained compensation for the underlying disease, targeted levels of glycemia and lipidogram, normalization of body weight, which will reduce cardiovascular risk in patients with type 2 diabetes. The active study of the influence of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on appetite regulation is one of the priority directions of modern diabetology.</p>}, number={3}, journal={Problems of Endocrine Pathology}, author={Laniush, F. V. and Urbanovych, A. M.}, year={2020}, month={Aug.}, pages={119-125} }